IDH1 R132H Point Mutation with Interpretation by Immunohistochemistry
Also known as: IDH1 IP
Use
This test is designed to identify the presence of the common IDH1 R132H mutation in diffuse gliomas via immunohistochemical staining. It detects the expression of the mutant IDH1 R132H protein, which is common in certain types of brain tumors. A positive test result may indicate the presence of the IDH1 R132H mutation, providing diagnostic and prognostic information for brain tumor classification and patient management.
Special Instructions
Not provided.
Limitations
This test specifically detects the IDH1 R132H mutation but cannot rule out the presence of other less common mutations in the IDH1 gene. Negative results do not completely exclude the possibility of an IDH1 mutation other than R132H. The test is not cleared or approved by the FDA and is performed in a CLIA-certified laboratory for clinical purposes only.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Mutant IDH1 R132H
Protein
LOINC Codes
- 31208-2 - Specimen source
- 55229-9 - Immune stain study
- 94736-6 - Tissue block ID Spec
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
3 slides
Container
Tissue transport kit (ARUP supply #47808)
Collection Instructions
Formalin fix and paraffin embed the specimen. Protect slides from excessive heat. Transport tissue block or 5 unstained 3- to 5-micron thick sections on positively charged slides.
Storage Instructions
Room temperature; Refrigerated acceptable. Ship in cooled container during summer.
Causes for Rejection
Paraffin block with no tumor tissue. Specimens fixed in other fixatives than 10 percent neutral buffered formalin. Decalcified specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
| Refrigerated | Indefinitely |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant